L&K BioMed announced on Wednesday that its U.S. subsidiary, L&K Spine, recently showcased its product lineup at the American Association of Neurological Surgeons (AANS) conference in Texas.
At the event, L&K Spine operated a standalone booth, offering demonstrations of its height-expandable cages and flagship products to medical professionals from various countries. This provided an opportunity for on-site validation of the company’s technological prowess and clinical utility.
The conference yielded positive feedback on BluEX-C and Castleloc P 2.0, cervical products currently undergoing the U.S. Food and Drug Administration (FDA) approval. The height-expandable cervical product BluEX-C garnered significant interest and potential adoption, standing out with its competitive edge in a market with limited supply options.
Key U.S. distributors also expressed strong interest in the new products, which the company sees as a stepping stone to bolster its local supply chain and operational capabilities.
Furthermore, L&K BioMed is actively expanding its U.S. supply network through partnerships with major global firms, aiming to cement its position in the local market.
A spokesperson for L&K BioMed stated that the U.S. medical device market is a global leader, demanding high regulatory standards and clinical reliability. The market expansion serves as a crucial indicator of the technological and product competitiveness. It’s building a robust market foundation by cultivating clinical credibility through collaboration with local healthcare professionals.
The spokesperson added that leveraging insights from this conference, it plans to reinforce our foundation for future growth. It’ll gradually implement product enhancements and tailored business strategies, including for the U.S. market, to achieve concrete results.
In February, L&K BioMed signed an agreement to acquire new assets, including land and buildings, to expand its global supply chain in partnership with a major international firm.
The company intends to use this acquisition as a springboard for introducing advanced automated equipment, establishing a dedicated production line for its global partner.
The newly acquired land spans approximately 3,292 square meters. L&K BioMed aims to boost its production capacity and strengthen its research and development (R&D) infrastructure through facility expansion and equipment upgrades at the new site.
Currently, L&K BioMed manufactures its entire range of spinal implants at existing facilities, while outsourcing some production.
To expand capacity and ensure a stable supply chain, the company is making strategic investments. The new facility will focus on producing products for global partners and height-expandable cervical cages, effectively doubling overall production capacity to meet growing global demand.